Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

NCT05198843 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

1

Enrollment

NIH

Sponsor class

Stopped Other - Poor accrual

Conditions

Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Triple-Negative Breast Inflammatory Carcinoma

Interventions

DRUG: Dasatinib
DIETARY_SUPPLEMENT: Icosapent Ethyl

Sponsor

National Cancer Institute (NCI)